[Corrections] Correction to Lancet Infect Dis 2019; 19: 988–1000

21:48 EST 3 Dec 2019 | The Lancet

Dagnew AF, Ilhan A, Lee W-S, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised clinical trials and post-hoc efficacy analysis. Lancet Infect Dis 2019; 19: 988–1000—In this Article, in page 997, the final paragraph of the results section should have stated “…excluding non-Hodgkin B-cell lymphoma and chronic lymphocytic leukaemia stratum (two [1·4%] of 148 vaccine group participants and one [0·8%] of 130 placebo group participants; per-protocol cohort for humoral immunogenicity, month 2).” This correction has been made to the online version as of Dec 3, 2019.

Original Article: [Corrections] Correction to Lancet Infect Dis 2019; 19: 988–1000


More From BioPortfolio on "[Corrections] Correction to Lancet Infect Dis 2019; 19: 988–1000"

Quick Search

Relevant Topics

Recombinant DNA
Recombinant DNA is the formation of a novel DNA sequence by the formation of two DNA strands. These are taken from two different organisms. These recombinant DNA molecules can be made with recombinant DNA technology. The procedure is to cut the DNA of ...

A vaccine is any preparation intended to produce immunity to a disease by stimulating the production of antibodies. It creates immunity but does not cause the disease. There are several differnt types of vaccine avalable; Killed microorganisms; which s...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...